Close

Clinical Trials

Thrombolytic Science Initiates Phase 2 Clinical Trial of its Novel Treatment Regimen for Ischemic Stroke

Thrombolytic Science, LLC (TSI) today announced initiation of a Phase 2 clinical trial to confirm the efficacy and safety of its sequential dual-treatment regimen of low-dose tissue plasminogen activator (tPA) and HisproUK (TSI’s mutant prourokinase ) in patients who...

CRF Health Partners Innovative US Biotech with TrialMax® eCOA Solution for Phase III Prostate Oncology Study

CRF Health, the leading provider of patient-centered eSource technology solutions for the life sciences industry, announced that its TrialMax® Slate solution has been selected by a US biotech company for a global Phase III prostate cancer study. ...

Celtaxsys Announces Results of Phase 2 Trial Showing Clinically Meaningful Improvement in Pulmonary Exacerbations in Cystic Fibrosis Patients

Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with rare inflammatory diseases, announced top line results of its Phase 2 EMPIRE-CF trial evaluating oral, once daily anti-inflammatory molecule, acebilustat, for the treatment of...

Servier and Galapagos announce start of global ROCCELLA Phase 2 clinical trial with S201086/GLPG1972 in osteoarthritis

Servier, an independent international pharmaceutical company, and the company Galapagos NV announce the start of a global Phase 2 trial with S201086/GLPG1972 in knee osteoarthritis patients: ROCCELLA. Servier and Galapagos have submitted and will further submit...

AbbVie Provides Update on Phase 3 Study of Ibrutinib in Blood Cancer Diffuse Large B-Cell Lymphoma and Ongoing Ibrutinib Clinical Program

AbbVie , a research-based global biopharmaceutical company, announced an update on a Phase 3 study (DBL3001) of ibrutinib (IMBRUVICA®) in untreated diffuse large B-cell lymphoma , an aggressive form of non-Hodgkin lymphoma. IMBRUVICA is a first-in-class...

Codexis Doses First Subjects in Phase 1a Trial of CDX-6114

Codexis, Inc , a leading protein engineering company, announces that it has dosed the first subjects in a first-in-human Phase 1a dose-escalation trial with CDX-6114, its orally administered enzyme therapeutic being developed for the management of phenylketonuria (PKU). ...

Aminex Therapeutics Initiates First Clinical Trial of Novel Immunotherapy AMXT 1501 + DFMO in Cancer Patients

Aminex Therapeutics, Inc., a clinical-stage drug development company focused on advancing a novel cancer immunotherapy, announced it received clearance from the FDA to initiate the first Phase 1 clinical trial of its immuno-oncology drug candidate AMXT 1501. ...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read